Patent Approval Reinforces Nexalin’s Leadership in Non-Invasive Brain Stimulation for Addiction Treatment HOUSTON, TX, April 14, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) ...
HOUSTON, TX, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NXL) (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the ...
(LANSING, MICH) The Michigan Department of Insurance and Financial Services (DIFS) announced that more Michiganders are appealing health insurance claim denials under the Patient's Right to ...
(RTTNews) - Nexalin Technology, Inc. (NXL) has highlighted a growing body of peer-reviewed neuroimaging research that reinforces its Deep Intracranial Frequency Stimulation (DIFS) technology as a ...
Patent Strengthens Nexalin’s Intellectual Property Portfolio and Highlights the Potential of DIFS™ Technology in Addressing Substance Use Disorders, Including Opioids, Alcohol, Cocaine and ...
Nexalin Technology (NXL) announces the publication of a landmark study in the Journal of Affective Disorders demonstrating the potential efficacy of its proprietary DIFS technology. The research ...
LANSING, Mich. (WLNS) — The Michigan Department of Insurance and Financial Services (DIFS) and the Michigan Department of Health and Human Services (MDHHS) remind residents that most health insurance ...
HOUSTON, TX, April 14, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NXL) (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results